PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2014 | 10 | 1 |
Article title

Inclusion body myositis – pathomechanism and lessons from genetics

Content
Title variants
Languages of publication
EN
Abstracts
EN
Inclusion body myositis is a rare, late-onset
myopathy. Both inflammatory and myodegenerative
features play an important role in their pathogenesis.
Overlapping clinicopathological entities are the familial
inclusion body myopathies with or without dementia.
These myopathies share several clinical and pathological
features with the sporadic inflammatory disease.
Therefore, better understanding of the genetic basis and
pathomechanism of these rare familial cases may advance
our knowledge and enable more effective treatment
options in sporadic IBM, which is currently considered a
relentlessly progressive incurable disease.
Publisher
Journal
Year
Volume
10
Issue
1
Physical description
Dates
received
18 - 2 - 2014
online
26 - 2 - 2015
accepted
30 - 1 - 2015
References
  • [1] Dalakas, M.C., Sporadic inclusion body myositis – diagnosis,pathogenesis and therapeutic strategies. Nat Clin Pract Neurol,2006. 2: p. 437-447[Crossref]
  • [2] Munshi, S.K., et al., Inclusion body myositis: an underdiagnosedmyopathy of older people. Age Ageing, 2006. 35: p.91-94[Crossref]
  • [3] Bodoki, L., et al., [Inclusion body myositis.] Ideggy Szle, 2015.68: p. 59-67
  • [4] Bodoki, L., et al., Inclusion body myositis – a case basedclinicopathological update. Cent Eur J Med, 2014 9: p. 80-85[WoS]
  • [5] Greenberg, S.A., Inclusion body myositis. Curr Opin Rheumatol,2011. 23: p. 574-578[WoS][Crossref]
  • [6] Needham, M., et al., Genetics of inclusion-body myositis.Muscle Nerve, 2007. 35: p. 549-561[Crossref][WoS]
  • [7] Koffman, B.M., et al., HLA allele distribution distinguishessporadic inclusion body myositis from hereditary inclusionbody myopathies. J Neuroimmunol, 1998. 84: p. 139-142[Crossref]
  • [8] Cai, H., et al., Clinical, pathological, and genetic mutationanalysis of sporadic inclusion body myositis in Japanesepeople. J Neurol, 2012. 259: p. 1913-1922[WoS]
  • [9] Mastaglia, F.L., Sporadic inclusion body myositis: variabilityin prevalence and phenotype and influence of the MHC. ActaMyol, 2009. 28: p. 66-71
  • [10] Rojana-Udomsart, A., et al., Analysis of HLA-DRB3 alleles andsupertypical genotypes in the MHC Class II region in sporadicinclusion body myositis. J Neuroimmunol, 2013. 254: p. 174-177
  • [11] Broccolini, A., et al., Hereditary inclusion-body myopathy withsparing of the quadriceps: the many tiles of an incompletepuzzle. Acta Myol, 2011. 30: p. 91-95
  • [12] Fischer, C., et al., Cell stress molecules in the skeletal muscleof GNE myopathy. BMC Neurol, 2013. 13: p. 24-24[Crossref][WoS]
  • [13] Boyden, S.E., et al., Molecular diagnosis of hereditary inclusionbody myopathy by linkage analysis and identification of a novelsplice site mutation in GNE. BMC Medical Genetics, 2011. 12[WoS][Crossref]
  • [14] Greenberg, S.A., Theories of the pathogenesis of inclusionbody myositis. Curr Rheumatol Rep, 2010. 12: p. 221-228[Crossref]
  • [15] Askanas, V., et al., Sporadic inclusion-body myositis:conformational multifactorial ageing-related degenerativemuscle disease associated with proteasomal and lysosomalinhibition, endoplasmic reticulum stress, and accumulation ofamyloid-β42 oligomers and phosphorylated tau. Presse Med,2011. 40: p. 219-235
  • [16] Weihl, C.C., et al., Sporadic inclusion body myositis: possiblepathogenesis inferred from biomarkers. Curr Opin Neurol,2010. 23: p. 482-488[WoS][Crossref]
  • [17] Yamashita, S., et al., Optineurin is potentially associated withTDP-43 and involved in the pathogenesis of inclusion bodymyositis. Neuropathol Appl Neurobiol, 2013. 39: p. 406-416[WoS][Crossref]
  • [18] Hortobagyi, T., et al., Optineurin inclusions occur in aminority of TDP-43 positive ALS and FTLD-TDP cases and arerarely observed in other neurodegenerative disorders. ActaNeuropathol, 2011. 121: p. 519-527[Crossref][WoS]
  • [19] Ivanidze, J., et al., Inclusion body myositis: lasermicrodissection reveals differential up-regulation of IFN-γsignaling cascade in attacked versus nonattacked myofibers.Am J Pathol, 2011. 179: p. 1347-1359[WoS]
  • [20] Salajegheh, M., et al., Autoantibodies against a 43 KDa muscleprotein in inclusion body myositis. PLoS One, 2011. 6[WoS]
  • [21] Quick, A., et al., Mechanisms of action of intravenous immunoglobulinin inflammatory muscle disease. Curr Rheumatol Rep,2011. 13: p. 192-198[WoS][Crossref]
  • [22] Kierdaszuk, B., et al., Inclusion body myositis: therapeuticapproaches. A case report. Neurol Neurochir Pol, 2011. 45: p.68-73
  • [23] Lloyd, T.E., Novel therapeutic approaches for inclusion bodymyositis. Curr Opin Rheumatol, 2010. 22: p. 658-664[Crossref][WoS]
  • [24] Barca, E., et al., ANT1 is reduced in sporadic inclusion bodymyositis. Neurol Sci, 2013. 34: p. 217-224[Crossref]
  • [25] Dalakas, M.C., et al., Effect of Alemtuzumab (CAMPATH 1-H)in patients with inclusion-body myositis. Brain, 2009. 132: p.1536-1544[WoS]
  • [26] Benveniste, O., et al., International Workshop on InclusionBody Myositis held at the Institute of Myology, Paris, on 29 May2009. Neuromuscular Disorders, 2010. 20: p. 414-421
  • [27] Sancricca, C., et al., Pilot trial of simvastatin in the treatment ofsporadic inclusion-body myositis. Neurological Sciences, 2011.32: p. 841-847[Crossref][WoS]
  • [28] Alexanderson, H., Exercise in inflammatory myopathies,including inclusion body myositis. Curr Rheumatol Rep, 2012.14: p. 244-251[Crossref][WoS]
  • [29] Cox, F.M., et al., A 12-year follow-up in sporadic inclusion bodymyositis: an end stage with major disabilities. Brain, 2011. 134:p. 3167-3175[WoS]
  • [30] Fanganiello, R.D., et al., A Brazilian family with hereditaryinclusion body myopathy associated with Paget disease ofbone and frontotemporal dementia. Braz J Med Biol Res, 2011.44: p. 374-380[Crossref][WoS]
  • [31] Greenberg, S.A., et al., Nuclear localization of valosincontainingprotein in normal muscle and muscle affected byinclusion-body myositis. Muscle Nerve, 2007. 36: p. 447-454[Crossref]
  • [32] Kimonis, V.E., et al., VCP disease associated with myopathy,Paget disease of bone and frontotemporal dementia: reviewof a unique disorder. Biochim Biophys Acta, 2008. 1782: p.744-748[WoS]
  • [33] Weihl, C.C., et al., Valosin-containing protein disease: inclusionbody myopathy with Paget’s disease of the bone and frontotemporaldementia. Neuromuscul Disord, 2009. 19: p. 308-315[Crossref]
  • [34] Kimonis, V.E., et al., Clinical studies in familial VCP myopathyassociated with Paget disease of bone and frontotemporaldementia. Am J Med Genet A, 2008. 146A: p. 745-757[WoS]
  • [35] Mackenzie, I.R.A., et al., Nomenclature and nosologyfor neuropathologic subtypes of frontotemporal lobardegeneration: an update. Acta Neuropathol, 2010. 119: p. 1-4[WoS][Crossref]
  • [36] Strong, M., et al., Amyotrophic lateral sclerosis, Primary lateralsclerosis and Spinal muscular atrophy, in Neurodegeneration:The molecular pathology of dementia and movement disorders,Dickson DW, et al., Editors. 2011, Wiley-Blackwell.
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.-psjd-doi-10_1515_med-2015-0030
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.